Xinyan Jia
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation.
Journal: Oncogene
Published: June 23, 2025
Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139].
Journal: International immunopharmacology
Published: June 22, 2024
Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis.
Journal: Journal of biomedical science
Published: May 05, 2024
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in multiple myeloma.
Journal: Translational oncology
Published: February 21, 2024
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
Journal: Acta biochimica et biophysica Sinica
Published: November 27, 2023
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
Journal: Journal of translational medicine
Published: September 21, 2023
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory.
Journal: International immunopharmacology
Published: August 12, 2023
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells.
Journal: International immunopharmacology
Published: July 26, 2023
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
Journal: Acta biochimica et biophysica Sinica
Published: February 23, 2023
Last Updated: 09/26/2026